Serum TWEAK in acne vulgaris: An unknown soldier.
TWEAK
acne
inflammation
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
07
11
2018
revised:
17
04
2019
accepted:
08
05
2019
pubmed:
29
5
2019
medline:
20
11
2020
entrez:
29
5
2019
Statut:
ppublish
Résumé
TWEAK is an inflammatory cytokine which is involved in the development of many inflammatory disorders. This study aimed to evaluate serum levels of TWEAK in patients with acne vulgaris. This case-controlled study included 100 acne vulgaris patients divided into two groups. Group 1 included 25 patients with moderate acne and 25 patients with severe acne. Group 2 consisted of 50 acne-free control subjects. Acne was graded by the Global Acne Grading System (GAGS). Serum TWEAK was measured by ELISA kits. Acne patients had significant elevation in TWEAK serum levels when compared to the control subjects (P < 0.001). TWEAK serum levels did not show significant difference regarding disease grade, postacne scar, and hyperpigmentation (P value = 0.43, 0.37, 0.80, 0.67, respectively). TWEAK levels were not affected by any of the studied variables except for the significant negative correlation between its levels and the disease duration in severe acne group only (r = -0.42, P = 0.03). TWEAK may be involved in acne vulgaris development, but more studies are needed to clarify its role.
Sections du résumé
BACKGROUND
BACKGROUND
TWEAK is an inflammatory cytokine which is involved in the development of many inflammatory disorders.
AIMS
OBJECTIVE
This study aimed to evaluate serum levels of TWEAK in patients with acne vulgaris.
SUBJECTS AND METHODS
METHODS
This case-controlled study included 100 acne vulgaris patients divided into two groups. Group 1 included 25 patients with moderate acne and 25 patients with severe acne. Group 2 consisted of 50 acne-free control subjects. Acne was graded by the Global Acne Grading System (GAGS). Serum TWEAK was measured by ELISA kits.
RESULTS
RESULTS
Acne patients had significant elevation in TWEAK serum levels when compared to the control subjects (P < 0.001). TWEAK serum levels did not show significant difference regarding disease grade, postacne scar, and hyperpigmentation (P value = 0.43, 0.37, 0.80, 0.67, respectively). TWEAK levels were not affected by any of the studied variables except for the significant negative correlation between its levels and the disease duration in severe acne group only (r = -0.42, P = 0.03).
CONCLUSION
CONCLUSIONS
TWEAK may be involved in acne vulgaris development, but more studies are needed to clarify its role.
Substances chimiques
Cytokine TWEAK
0
TNFSF12 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-518Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Knutsen-Larson S, Dawson A, Dunnick C, Dellavalle R. Acne vulgaris: pathogenesis, treatment, and needs assessment. Dermatol Clin. 2012;30(1):99-106.
Mills OH, Criscito MC, Schlesinger TE, Verdicchio R, Szoke E. Addressing free radical oxidation in acne vulgaris. J Clin Aesthet Dermatol. 2016;9(1):25.
Chen J, Wei L, Xia Y. Roles of tumour necrosis factor-related weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in lupus nephritis. Nephrology. 2017;22(2):101-106.
Peternel S, Manestar-Blažić T, Brajac I, Prpić-Massari L, Kaštelan M. Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: association with proliferation and differentiation of keratinocytes. J Cutan Pathol. 2011;38(10):780-789.
Burkhart CG, Burkhart CN. Expanding the microcomedone theory and acne therapeutics: propionibacterium acnes biofilm produces biological glue that holds corneocytes together to form plug. J Am Acad Dermatol. 2007;57(4):722-724.
Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36(6):416-418.
England JM, Rowan RM, van Assendelft OW, et al. Protocol for evaluation of automated blood cell counters. International committee for standardization in hematology (ICSH). Clin Lab Haematol. 1984;6(1):69-84.
Choe JY, Kim SK. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus. Inflamm Res. 2016;65(6):479-488.
Park MC, Jung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol. 2008;37(3):173-178.
Liu Q, Xiao S, Xia Y. TWEAK/Fn14 activation participates in skin inflammation. Mediators Inflamm. 2017;6746870.
Li M, Chen T, Guo Z, Li J, Cao N. Tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 are expressed in urticarial vasculitis. J Dermatol. 2013;40(11):891-895.
Chen T, Guo ZP, Li MM, et al. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura. Clin Exp Immunol. 2011;166(1):64-71.
Xia L, Shen H, Xiao W, Lu J. Increased serum TWEAK levels in psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine. 2011;53(3):289-291.
Chen Y, Lind Enoksson S, Johansson C, et al. The expression of BAFF, APRIL and TWEAK is altered in eczema skin but not in the circulation of atopic and seborrheic eczema patients. PLoS ONE. 2011;6(7):e22202.
Peng QL, Shu XM, Tian XL, Lu X, Wang GC Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis. Arthritis Res Ther. 2014;16(1):R26.
Bover LC, Cardo-Vila M, Kuniyasu A, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol. 2007;178(12):8183-8194.
Moreno JA, Muñoz-García B, Martín-Ventura JL, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207(1):103-110.
Bilgiç Ö, Sivrikaya A, Toker A, Ünlü A, Altınyazar C. Serum levels of TWEAK in patients with psoriasis vulgaris. Cytokine. 2016;77:10-13.
Sabour Alaoui S, Dessirier V, de Araujo E, et al. TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus. PLoS ONE. 2012;7(3):e33609.
Zimmermann M, Koreck A, Meyer N, et al. TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol. 2011;127(1):200-207.
Turkmen K, Tonbul HZ, Erdur FM,et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol. 2013;14(1):144.
Kowal-Bielecka O, Bielecki M, Guiducci S, et al. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther. 2013;15(3):R69.
Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR. Serum levels of TWEAK and scavenger receptor CD163 in Type 1 diabetes mellitus: relationship with cardiovascular risk factors. A Case-Control Study. PLoS ONE. 2012;7(8):e43919.
Koçak E, Köklü S, Başar O, et al. Evaluation of serum TWEAK concentration in patients with acute pancreatitis. Scand J Clin Lab Invest. 2012;72(3):192-196.
Yanaba K, Yoshizaki A, Muroi E, et al. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol. 2009;36(8):1657-1662.